# Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)

> **NCT05233332** · PHASE2 · UNKNOWN · sponsor: **Shanghai Kechow Pharma, Inc.** · enrollment: 186 (estimated)

## Conditions studied

- CRC

## Interventions

- **DRUG:** HL-085
- **DRUG:** Vemurafenib

## Key facts

- **NCT ID:** NCT05233332
- **Lead sponsor:** Shanghai Kechow Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-24
- **Primary completion:** 2024-01-20
- **Final completion:** 2024-07-20
- **Target enrollment:** 186 (ESTIMATED)
- **Last updated:** 2023-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05233332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05233332, "Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT05233332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*